Ann: Halucenex Update, page-4

Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is
pleased to advise that its wholly-owned, Canadian based psychedelics subsidiary, Halucenex Life
Sciences Inc. (“Halucenex”) has been included on a list of companies that can provide psychedelic
compounds to researchers and patients under the SAP. The SAP is a federal program that allows
healthcare professionals to apply for access to non-marketed medications that have not yet been
approved for sale when such medications show clinical evidence of safety and efficacy and are
intended to treat patients with severe or life-threatening illnessii.

it will take years before clinical evidence help push legislation changes and commercializing this into a profitable revenue stream.... until that happens.. the cash burn is not sustainable and imagine the amount of capital raises needed to keep this afloat to reach that goal...

but I guess as long as you the holder is happy.. that's most important. =)